Dose-finding and efficacy phase II study of inecalcitol, a new VDR agonist, in combination with docetaxel-prednisone regimen for patients (pts) with castration-resistant prostate cancer (CRPC).

被引：0
|
作者：
Medioni, J.
Ferrero, J.
Deplanque, G.
Maurina, T.
Rodier, J. P.
Raymond, E.
Allyon, J.
Renaux, S.
Dufour-Lamartinie, J.
Oudard, S.
机构：
[1] Georges Pompidou European Hosp, Paris, France
[2] Ctr Antoine Lacassagne, F-06054 Nice, France
[3] Grp Hosp St Joseph, Paris, France
[4] Jean Minjoz Hosp, Besancon, France
[5] Hop Xavier Bichat, Paris, France
[6] Beaujon Univ Hosp, Clichy, France
[7] Hybrigenics, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.4605
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4605
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Einstein, David Johnson
    Choudhury, Atish Dipankar
    Saylor, Philip James
    Werner, Lillian
    Erlander, Mark G.
    Ridinger, Maya
    Bubley, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [32] A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Einstein, David Johnson
    Choudhury, Atish Dipankar
    Saylor, Philip James
    Patterson, Jesse Christopher
    Croucher, Peter
    Ridinger, Maya
    Erlander, Mark G.
    Yaffe, Michael B.
    Bubley, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [33] Phase I study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer (CRPC) previously treated with docetaxel-based therapy.
    Singal, R.
    Ramachandran, K.
    Gordian, E.
    Reis, I. M.
    Zhao, W.
    Quintero, C. A.
    Mayo, C.
    Auguste, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [34] Predictive factors of response to docetaxel (DOC) rechallenge (ReC) in castration-resistant prostate cancer (CRPC) patients (pts).
    Veccia, A.
    Caffo, O.
    Brugnara, S.
    Caldara, A.
    di Pasquale, M. C.
    Ferro, A.
    Frisinghelli, M.
    Murgia, V.
    Soini, B.
    Valduga, F.
    Pappagallo, G. L.
    Galligioni, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [35] A PHASE II STUDY OF SB939 IN PATIENTS (PTS) WITH CASTRATION RESISTANT PROSTATE CANCER (CRPC)
    Eigl, B. J.
    North, S.
    Winquist, E.
    Powers, J.
    Good, J.
    Sharma, M.
    Squire, J.
    Cox, M.
    Eisenhauer, E. A.
    Chi, K.
    ANNALS OF ONCOLOGY, 2012, 23 : 304 - 304
  • [36] Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Adesunloye, Bamidele
    Huang, Xuan
    Ning, Yangmin M.
    Madan, Ravi A.
    Gulley, James L.
    Beatson, Melony
    Kluetz, Paul Gustav
    Adelberg, David
    Arlen, Philip M.
    Parnes, Howard L.
    Mulquin, Marcia
    Steinberg, Seth M.
    Wright, John Joseph
    Trepel, Jane B.
    Dawson, Nancy Ann
    Chen, Clara
    Apolo, Andrea Borghese
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [37] Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients
    Buonerba, Carlo
    Federico, Piera
    D'Aniello, Carmine
    Rescigno, Pasquale
    Cavaliere, Carla
    Puglia, Livio
    Ferro, Matteo
    Altieri, Vincenzo
    Perdona, Sisto
    De Placido, Sabino
    Lorenzo, Giuseppe Di
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (06) : 1455 - 1461
  • [38] Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Huang, X.
    Ning, Y. M.
    Mulquin, M.
    Madan, R. A.
    Gulley, J. L.
    Kluetz, P. G.
    Adelberg, D.
    Arlen, P. M.
    Parnes, H. L.
    Adesunloye, B.
    Steinberg, S. M.
    Wright, J. J.
    Trepel, J. B.
    Chen, C.
    Bassim, C.
    Apolo, A. B.
    Figg, W. D.
    Dahut, W. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [39] Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts)with metastatic castration-resistant prostate cancer (mCRPC)
    Huang, X.
    Ning, Y. M.
    Gulley, J. L.
    Kluetz, P. G.
    Adelberg, D.
    Mulquin, M.
    Madan, R. A.
    Bassim, C.
    Figg, W. D.
    Dahut, W. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [40] Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients
    Carlo Buonerba
    Piera Federico
    Carmine D’Aniello
    Pasquale Rescigno
    Carla Cavaliere
    Livio Puglia
    Matteo Ferro
    Vincenzo Altieri
    Sisto Perdonà
    Sabino De Placido
    Giuseppe Di Lorenzo
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 1455 - 1461
12345